Shares of Ono Pharmaceutical Co. (OTCMKTS:OPHLF – Get Free Report) crossed below its 200-day moving average during trading on Thursday. The stock has a 200-day moving average of $14.87 and traded as low as $14.10. Ono Pharmaceutical shares last traded at $14.10, with a volume of 1,000 shares trading hands.
Wall Street Analysts Forecast Growth
Separately, Zacks Research lowered shares of Ono Pharmaceutical from a “strong-buy” rating to a “hold” rating in a report on Friday, September 4th. One investment analyst has rated the stock with a Hold rating. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold”.
Get Our Latest Analysis on OPHLF
Ono Pharmaceutical Stock Performance
The stock has a 50 day moving average price of $15.17 and a two-hundred day moving average price of $14.87. The company has a current ratio of 3.28, a quick ratio of 2.86 and a debt-to-equity ratio of 0.08. The company has a market cap of $6.63 billion, a price-to-earnings ratio of 13.43 and a beta of 0.38.
About Ono Pharmaceutical
Ono Pharmaceutical Co, Ltd. is a Japan-based research-driven pharmaceutical company focused on discovering, developing and commercializing prescription medicines. Its primary therapeutic areas include oncology, immunology, neurology and other specialty-care fields. The company develops medicines internally and also works with research institutions and global pharmaceutical partners.
Ono is best known internationally for Opdivo (nivolumab), an immune checkpoint inhibitor developed in collaboration with Bristol Myers Squibb and used in the treatment of multiple types of cancer.
See Also
- Five stocks we like better than Ono Pharmaceutical
- Phillips 66 Posts Strong Earnings But the Stock Doesn’t Care
- NXP Semiconductors Falls After Strong Earnings—Is the Sell-Off Overdone?
- GE Vernova’s Reservations Are Turning Into Real Orders—But the Market Still Wants More.
- Where’s the Beef? Trian-Led Buyout Proposal Values Wendy’s at $1.4B, But Is It Enough?
Receive News & Ratings for Ono Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ono Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.
